

THEIR VISION IS A MASTERPIECE For patients with wet AMD, BEOVU

**Dries
Better**

35% fewer
patients had
SRF and/or
IRF at 16
weeks* 1-4

**Dries
Faster**

Faster fluid
resolution
seen
as early as
4 & 8 weeks* 1-6

**For
Longer**

Longer
treatment
interval,
more than
50%
of patients
maintained
on q12w^{+1,2}

* vs Aflibercept
+ immediately after loading and until week 48



References:

1. Beovu Summary of Product Characteristics. Novartis; 2020. 2. Data on file. RTH258-C001 Clinical Study Report. Novartis; 2018. 3. Data on file. RTH258-C002 Clinical Study Report. Novartis; 2018. 4. Dugel PU, Koh A, Ogura Y, et al; on behalf of the HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72-123. 5. Singh R, et al. ARVO 2019 [Oral presentation]; 6. Holz FG, et al. EURETINA 2019 [Oral presentation]